Welcome to our dedicated page for Amicus Therapeut SEC filings (Ticker: FOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amicus Therapeutics, Inc. (NASDAQ: FOLD) SEC filings page on Stock Titan provides access to the company’s official disclosures as a rare disease biotechnology issuer. Amicus describes itself as a global, patient-dedicated biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases, including Fabry disease and late-onset Pompe disease.
Key filings for FOLD include current reports on Form 8-K that summarize material events and financial updates. For example, Amicus has filed 8-K reports to furnish press releases announcing quarterly financial results for periods ended June 30, 2025 and September 30, 2025. These filings identify the company’s common stock as listed on NASDAQ under the symbol FOLD and outline that the information provided under Item 2.02 (Results of Operations and Financial Condition) is furnished rather than filed for certain liability purposes.
Through its periodic reports and exhibits, Amicus details net product revenues for Galafold (migalastat) and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), operating expenses, non-GAAP measures and cash position. These documents also describe the company’s focus on rare disease medicines and provide context for its commercial performance and research investments.
Investors can also expect SEC filings related to significant corporate transactions. On December 19, 2025, Amicus and BioMarin Pharmaceutical Inc. announced a definitive agreement for BioMarin to acquire Amicus in an all-cash transaction, a development that would typically be reflected in transaction-related filings and proxy materials as the process advances, subject to regulatory and stockholder approvals.
On Stock Titan, Amicus filings are supplemented by AI-powered tools that help explain the content and structure of documents such as 8-Ks, quarterly reports and, when available, annual reports and proxy statements. Users can review real-time updates from EDGAR, track how Amicus reports on its rare disease portfolio and commercial performance, and examine the regulatory record that underpins analysis of FOLD as a biotechnology stock.
Amicus Therapeutics President and CEO Bradley L. Campbell reported an option exercise and share sale. On January 20, 2026, he exercised 75,000 stock options with an exercise price of $6.10 per share, receiving 75,000 shares of common stock. That same day, he sold 75,000 shares of common stock at a weighted average price of $14.3091 per share, with individual sale prices ranging from $14.30 to $14.32.
Following these transactions, Campbell directly owned 1,021,180 shares of Amicus Therapeutics common stock. All options exercised were fully vested and exercisable as of the transaction date. The filing notes that all transactions were carried out under a Rule 10b5-1 trading plan adopted on September 12, 2025.
Amicus Therapeutics, Inc. (FOLD) has agreed to be acquired by BioMarin Pharmaceutical Inc. in an all-cash merger at $14.50 per share. Lynx Merger Sub 1, Inc., a BioMarin subsidiary, will merge into Amicus, which will become a wholly owned BioMarin subsidiary.
After the merger, Amicus stock will be delisted from Nasdaq and deregistered, and stockholders will receive only the cash merger payment or, if properly perfected, an appraisal-based cash amount determined by the Delaware Court of Chancery. The deal requires approval by holders of a majority of Amicus’ outstanding common stock at a virtual special meeting in 2026, and a $175 million cash termination fee may be payable to BioMarin if the agreement ends under specified circumstances.
The board unanimously determined the merger is advisable and fair to stockholders and recommends voting “FOR” the merger agreement, the advisory compensation proposal, and the adjournment proposal.
Amicus Therapeutics insider plans Form 144 stock sale. A person identified through a 10b5-1 sales plan for Bradley Campbell filed notice to sell 75,000 shares of Amicus Therapeutics common stock through Morgan Stanley Smith Barney on the NASDAQ. The planned sale has an aggregate market value of $1,074,750.00 based on the figures in the notice, versus 308,533,548 Amicus common shares outstanding.
The shares to be sold were acquired on 01/20/2026 by exercising stock options from the issuer for cash on the same date. The filing also lists prior sales under the same 10b5-1 sales plan over the past three months, including 70,426 shares sold on 12/15/2025 for $763,509.39 and other smaller blocks, all in Amicus common stock.
Amicus Therapeutics Chief Development Officer Jeff Castelli filed a Form 4 reporting two non-derivative transactions in the company’s common stock. On January 2, 2026, a transaction coded “F” involved the disposition of 6,905 shares at $14.27 per share, leaving 432,413 shares beneficially owned directly.
On January 3, 2026, a second “F” coded transaction reported the disposition of 23,102 shares at $14.27 per share, resulting in 409,311 shares of common stock beneficially owned directly after the transaction.
Amicus Therapeutics' president and CEO, who also serves as a director, reported option exercises and share sales in the company’s stock. On December 15, 2025, the insider exercised 70,426 stock options at an exercise price of $9.03 per share, acquiring the same number of common shares. On the same date, the insider sold 77,926 shares of common stock at a weighted average price of $10.8566 per share, with individual sale prices ranging from $10.60 to $11.11.
After these transactions, the insider directly beneficially owned 1,129,782 shares of Amicus Therapeutics common stock and held no remaining derivative securities from this option grant. All of the options exercised were already fully vested and exercisable, and all reported trades were carried out under a Rule 10b5-1 trading plan adopted on September 13, 2024.
Amicus Therapeutics, Inc. reported an insider stock transaction by its Chief People Officer. On 12/15/2025, the officer sold 25,643 shares of common stock at $11 per share. After this sale, the officer beneficially owned 271,332 shares of Amicus Therapeutics common stock.
All of the reported transactions were carried out under a pre-established Rule 10b5-1 trading plan that the reporting person adopted on March 14, 2025, indicating the sales were made according to a predetermined schedule rather than discretionary market timing.
Amicus Therapeutics (FOLD) reported an insider transaction by its Chief People Officer. On 11/04/2025, the officer sold 25,643 shares of common stock at a $9.5098 weighted-average price (range $9.50–$9.54).
Following the sale, the officer beneficially owns 322,618 shares, held directly. The transactions were effected under a Rule 10b5-1 trading plan adopted on March 14, 2025.
Amicus Therapeutics reported stronger Q3 2025 results. Net product sales were $169.1 million, up from $141.5 million. The company posted net income of $17.3 million versus a loss a year ago. For the first nine months, sales reached $449.0 million and net loss narrowed to $28.8 million.
Galafold generated $371.5 million in year-to-date revenue, while Pombiliti + Opfolda contributed $77.5 million. Gross profit for the first nine months was $402.6 million. Operating cash flow was $16.9 million for the period. Cash, cash equivalents, and marketable securities totaled $263.8 million as of September 30, 2025.
Long-term debt carrying value was $392.0 million on a $400.0 million senior secured term loan due 2029. Inventory increased to $177.9 million to support commercial growth. The company recorded a $30 million upfront R&D expense tied to a U.S. license for Dimerix’s DMX-200. Shares outstanding were 308,533,548 as of October 24, 2025.
Amicus Therapeutics (FOLD) furnished an update on its recent performance, announcing financial results for the quarter ended September 30, 2025. The company issued a press release and will host a conference call and webcast on November 4, 2025 to discuss third‑quarter results.
The materials were provided under Item 2.02 and are furnished, not filed. Attached exhibits include the press release (Exhibit 99.1) and conference call presentation materials (Exhibit 99.2).
Amicus Therapeutics (FOLD) insider transaction: Simon N.R. Harford, identified as Chief Financial Officer and reporting person, reported a sale of 12,529 shares of Amicus common stock on 08/21/2025 at a reported price of $7.60 per share. After this transaction he is reported to beneficially own 214,898 shares. The Form 4 is signed by an attorney-in-fact on 08/25/2025.